ABSTRACT

Introduction: Several malaria vaccines are under various phases of development with some promising results. In placental malaria (PM) a deliberately anti-disease approach is considered as many studies have underlined the key role of VAR2CSA protein, which therefore represents the leading vaccine candidate. However, evidence indicates that VAR2CSA antigenic polymorphism remains an obstacle to overcome.

Areas covered: This review analyzes the progress made thus far in developing a VAR2CSA-based vaccine, and addresses the current issues and challenges that must be overcome to develop an effective PM vaccine.

Expert opinion: Phase I trials of PAMVAC and PRIMVAC VAR2CSA vaccines have shown more or less satisfactory results with regards to safety and immunogenicity. The second generation of VAR2CSA-based vaccines could benefit from optimization approaches to broaden the activity spectrum against various placenta-binding isolates through continued advances in the structural understanding of the interaction with CSA.

摘要

简介：几种疟疾疫苗正处于不同的开发阶段，并取得了一些有希望的结果。在胎盘疟疾 (PM) 中，考虑了一种有意的抗疾病方法，因为许多研究强调了 VAR2CSA 蛋白的关键作用，因此它代表了主要的候选疫苗。然而，证据表明 VAR2CSA 抗原多态性仍然是一个需要克服的障碍。

涵盖的领域：本综述分析了迄今为止在开发基于 VAR2CSA 的疫苗方面取得的进展，并解决了开发有效 PM 疫苗必须克服的当前问题和挑战。

专家意见： PAMVAC 和 PRIMVAC VAR2CSA 疫苗的 I 期试验在安全性和免疫原性方面或​​多或少显示出令人满意的结果。第二代基于 VAR2CSA 的疫苗可以受益于优化方法，通过对与 CSA 相互作用的结构理解的不断进步，拓宽针对各种胎盘结合分离株的活性谱。